Tagged with Hong Kong

Hong Kong Charles Ng and Simon Tsang of InvestHK, Hong Kong’s investment promotion agency, discuss the territory’s strengths in the life sciences sector, the potential of the HK industry to grow further, and its regional significance. The Swiss-based International Institute for Management Development (IMD) recently placed Hong Kong at the top of…

Hong Kong Scott Curley, general manager of Astra Zeneca Hong Kong, discusses how his affiliate managed to achieve its successful product launch track record; shares his insights on the key specificities of Hong Kong and further explains why it is an important market for Astra Zeneca’s global R&D. Having previously worked extensively…

Hong Kong Professor Cheng, managing director of the Hong Kong Institute of Biotechnology, introduces the organization’s mission to improve development of biotechnology and traditional Chinese medicine sectors as well as the main challenges ahead. What is the mandate of the Hong Kong Institute of Biotechnology (HKIB)? “Our mission statement was – and…

Hong Kong Alexandre de Muralt, the man behind Merck’s operations in Hong Kong and Taiwan discusses the nuances of these two local markets. In addition, he shares his insights on how Merck’s transformation has impacted local affiliates. Can you begin by telling us about Merck’s strategic transformation in recent years? “Founded in…

Hong Kong The Ming Wai Lau Center for Reparative Medicine was established in October 2016 as the first international arm of Karolinska Institute (KI) in over 200 years! What is the Center’s mission? “Hong Kong has been a trading port for centuries, and this is something Hong Kong can continue to leverage…

Hong Kong Hybribio is a very interesting company, being founded in Hong Kong and now headquartered in Guangzhou as one of the leading providers of in-vitro diagnostic (IVD) assays in Greater China with significant international presence as well. Can you tell us more about the company’s positioning today? “We have launched several…

Hong Kong William Lai YF, CEO of Fortune Pharmacal, discusses the Hong Kong OTC market, the company’s internationalization strategy, and its expanding manufacturing footprint. Could you please introduce us to Fortune Pharmacal? What sets you apart from other OTC companies? “We follow the highest standards by always exploring what the ‘big boys’…

Hong Kong Dr. Cecilia Pang, Biotechnology Director of the Hong Kong SAR Government’s Innovation and Technology Commission (ITC), discusses ITC’s mandate to develop the necessary infrastructure in order to foster Hong Kong’s innovation and technology environment, the increasing importance and relevance of the life sciences sector to Hong Kong, and the strengths…

Hong Kong Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the clinical trials environment in Hong Kong. Having been with the organization since nearly the beginning from 2000, how have you…

Hong Kong Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a little about the genesis of the company? Having previously studied and worked in the UK and US, I was asked…

Hong Kong Andy Barnett, general manager (Hong Kong and Macau) for Roche, discusses the highlights of his past two years managing a local affiliate instead of heading a global business line, the key factors behind Roche’s top-5 positioning in the local market, and the huge potential for innovation in aspects like digital…

Hong Kong Lawrence Wong, general manager of Ferring Pharmaceuticals in Hong Kong, discusses the important role of the Hong Kong affiliate in support of regional operations, the value of the Hong Kong market given that Ferring offers most of its global portfolio here, and how the company philosophy ‘People come first at…